Home HEALTH novartis: Novartis heart drug price may fall by 60% on generic rollouts

novartis: Novartis heart drug price may fall by 60% on generic rollouts

The price of top selling cardiac arrest drug sacubitril/valsartan sold by Swiss pharmaceutical company Novartis and its partners in India is expected fall as much as 60% with several Indian drugmakers gearing up to launch its generic version soon after the Delhi High Court cleared the decks for Indian generic makers by staying Novartis patents on the supra complex compound.

“At least 30-40 generic brands are expected to hit the market next in a couple of weeks,” said Hari Natarajan, managing director, Pronto Consult, that advises pharma companies on go-to-market strategy.

Natarajan said some of the big names of Indian drug companies including Sun Pharma, Cipla, Torrent Pharma, Eris Lifesciences, Natco Pharma and many more are gearing up to launch the drug.

Glenmark on Tuesday announced the launch of sacubitril and valsartan – under the brand name, ‘Sacu V’ at almost 60% lower price compared to Novartis’ Vymada. Glenmark priced a tablet at ₹19/dose of 50mg, Rs 35/tablet of 100mg and ₹45/tablet for a dose of 200mg. The tablets have to be taken twice a day.

Dr Reddy’s, which has acquired Cidmus (sacubitril/valsartan) from Novartis in April last year, has cut the price on Wednesday by over 60% to ₹29 a tablet of 50 mg, and 100 mg tablet by 49% to ₹49. Dr Reddy’s said it manufactures the drug in-house, including the active pharmaceutical ingredient (API) at a USFDA- approved facility.

Anticipating generic competition, JB Pharma has already cut the price of its version of sacubitril/valsartan sold under brand name Azmarda by half. JB like Dr Reddy’s bought the drug from Novartis in April last year.

Analysts said the entry of generic will lead to drop in value of the sacubitril/valsartan market, even as the volumes grow.

According to IQVIA sales data for the 12 month period ending December 2022, the total cardiology market is estimated to be ₹20,730 crore with an annual growth of 7.7% against the corresponding period last year. The market sacubitril and valsartan is estimated to be ₹514 crore with an annual growth of 37.2%. Specialist doctors who prescribe the drug are seeing huge potential, given the rising incidence of heart failure in India.

“Treatment with sacubitril/valsartan has demonstrated to significantly reduce mortality and the rates of hospitalisation and rehospitalisation for HF when compared to other heart failure drugs,” said Nishith chandra, director of interventional cardiology at Fortis Escorts Heart Institute.